Ping An Biomedical Co., Ltd 6-K, filed Jan 12, 2026
Ping An Biomedical Co., Ltd. (PASW)
About this 6-K
Ping An Biomedical Co., Ltd filed this 6-K on January 12, 2026.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of January, 2026
Commission File Number: 001-42155
| Ping An Biomedical Co., Ltd. | ||
| (Registrant’s Name) |
22/F, China United Plaza, 1002-1008, Tai Nan West Street,
Cheung Sha Wan, Kowloon, Hong Kong
(Address of Principal Executive Offices)
Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
Press Release
On January 9, 2026, Ping An Biomedical Co., Ltd. (the “Company”) issued two press releases. The first press announces entering into a series of share purchase agreements with several investors, and is filed as exhibit 99.1 to this Form 6-K. The second press announces the Company’s Strategic Investment in Future Biotechnology Group and is filed as exhibit 99.2 to this Form 6-K.
The foregoing descriptions of the press releases do not purport to be complete and are qualified in their entirety by reference to the respective press releases, which are filed as Exhibit 99.1 and Exhibit 99.2.
Financial Statements and Exhibits.
The following exhibits are being filed herewith:
1
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| PING AN BIOMEDICAL CO., LTD. | ||
| Date: January 12, 2026 | By: | /s/ Pijun Liu |
| Name: | Pijun Liu | |
| Title: | Chairman of the Board of Directors | |
2
Exhibit 99.1
Ping An Biomedical Co., Ltd. Receives Strategic
Investment from
Leading Industry Capital, Accelerating Growth in
Biopharmaceutical Innovation
Hong Kong, January 9, 2026 — Ping An Biomedical Co., Ltd. (NASDAQ: PASW) (hereinafter referred to as “Ping An Bio”) today announced that it has entered into a series of share purchase agreements with several investors.
Ping An Biomedical Co., Ltd. has entered into a series of share purchase agreements from several investors: Yao Jinbo, Chairman and CEO of 58 Group Inc.; Wang Donghui, Founder and Managing Partner of Amiba Capital Co., Ltd ; and Li Daxue, Chairman and CEO of Magcloud Group Co., Ltd and former Senior Vice President of JD.com and its Lifetime Honorary Advisor. This round of investment further strengthens the company’s long-term development in biopharmaceutical R&D, medical technology, and innovation .
Yao Jinbo of 58 Group: An Entrepreneur with a Proven Track Record of Capturing Megatrends
As one of China’s most representative internet entrepreneurs, Yao Jinbo is the Chairman and CEO of 58.com and a seasoned investor. His investment portfolio spans internet platforms, lifestyle services, technological innovation, and emerging industries, and he is well known for his forward-looking industrial judgment and long-term value investing philosophy.
Across multiple economic cycles, Yao has successfully invested in sectors with structural growth opportunities. His decision to invest in Ping An Bio marks another important strategic move in the biotechnology, healthcare, and pharmaceutical space. Industry observers view this not merely as a financial investment, but as a strong endorsement of Ping An Bio’s technology commercialization capabilities, business model, and long-term growth potential. According to public information, this is Yao Jinbo’s second major investment in the pharmaceutical sector within the past year, following his RMB 662 million investment in Yiming Pharmaceutical Holdings.
Wang Donghui of Amiba Capital: From Kingsoft CFO to Industrial Investor
Wang Donghui is a leading figure in China’s venture capital sector and the founding managing partner of Amiba Capital. He previously served as Chief Financial Officer and Senior Vice President of Kingsoft Corporation, working closely for many years with Lei Jun, founder of Xiaomi, and participating in Kingsoft’s Hong Kong IPO. Unlike purely financial investors, Wang places greater emphasis on a company’s underlying R&D capabilities and long-term value vision. He has made precise investments in multiple unicorn companies such as Meituan, Didi, Mogujie, and Jushuitan. As of 2025, Amiba Capital manages RMB 5 billion in RMB-denominated funds. Ping An Bio stands out in terms of its biopharmaceutical R&D pathways, technology implementation capabilities, and long-term technological moat, demonstrating rare potential for scalable growth.
Li Daxue of Magcloud Group: Former JD.com Vice President with a Strong Industry-Level Strategic Perspective
Li Daxue, former Vice President of JD.com and its Lifetime Honorary Advisor, brings deep expertise in technology R&D, platform-based operations, industrial integration, and large-scale enterprise management. His participation in Ping An Bio’s investor lineup signals strong capital market recognition of the company’s future transition from technological innovation to industrialization, scalability, and standardization.
In the biopharmaceutical sector, it is rare for a company to receive simultaneous recognition from both “technology capital” and “industrial capital.” This further highlights Ping An Bio’s unique position within the industry. Consensus among multiple top-tier investors is propelling the company toward a broader global stage.
Management Commentary
Liu Pijun, Chairman of the Board and Chief Executive Officer of Ping An Biomedical Co., Ltd, stated:
“We warmly welcome Mr. Li Daxue, Mr. Wang Donghui, and Mr. Yao Jinbo as strategic investors in the company. Each of them holds benchmark-level influence in technology innovation, capital operations, and internet platform ecosystems. Their participation will provide comprehensive empowerment to the company across technology strategy, capital planning, industrial resources, and ecosystem development.”
He further added:
“The company will continue to deepen its intelligent AI systems while accelerating innovation and commercialization in healthcare and biopharmaceutical technologies. Leveraging the international capital markets, we will continuously enhance our technological capabilities and global market influence, striving to become a technology-driven, diversified, and global leader in industrial upgrading.”
2
About Ping An Biomedical Co., Ltd
Ping An Biomedical Co., Ltd. is a one-stop SCM service provider in the apparel industry. It is also a forward-thinking company dedicated to delivering innovative solutions in healthcare and biomedical technology.
Safe Harbor and Informational Statement
This announcement contains “forward-looking” statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, including, without limitation, those with respect to the objectives, plans and strategies of the Company set forth herein and those preceded by or that include the words “believe,” “expect,” “anticipate,” “future,” “will,” “intend,” “plan,” “estimate” or similar expressions, are “forward-looking statements”. Although the Company’s management believes that such forward-looking statements are reasonable, it cannot guarantee that such expectations are, or will be, correct. These forward looking statements involve a number of risks and uncertainties, which could cause the Company’s future results to differ materially from those anticipated. These forward-looking statements can change as a result of many possible events or factors not all of which are known to the Company, which may include, without limitation, our ability to timely and accurately respond to changes in fashion trends and consumer preferences; management of customer concentration risk; reliance on third parties for supplies of raw materials, manufacturing services and transport infrastructure; changes in government policy in China; China’s overall economic conditions and local market economic conditions; our ability to expand through strategic acquisitions and establishment of new locations; compliance with government regulations; legislation or regulatory environments; geopolitical events, and other events and/or risks outlined in Ping An Biomedical Co., Ltd’s filings with the U.S. Securities and Exchange Commission. All information provided in this press release is as of the date of the issuance, and Ping An Biomedical Co., Ltd does not undertake any obligation to update any forward-looking statement, except as required under applicable law.
For more information, please contact:
Ping An Biomedical Co., Ltd.
Email: corpsec@pingan365.vip
Celestia Investor Relations
Email: investors@celestiair.com
3
Exhibit 99.2
Ping An Biomedical Co., Ltd Announces Strategic
Investment in Future
Biotechnology Group to Advance Collaborative Development of the
Biopharmaceutical Industry
Hong Kong, January 9, 2026 — Ping An Biomedical Co., Ltd (NASDAQ: PASW) (hereinafter referred to as “Ping An Bio”) announced that it has entered into a non-binding memorandum (the “Investment Memorandum”) with Future Biotechnology Group Co., Ltd (hereinafter referred to as “Future Biotechnology Group”).
The Investment Memorandum outlines an initial investment of US$30 million to be paid in cash, as well as subsequent acquisitions with a consideration, in aggregate, of US$60 million to be settled in cash and share issuances (the “Consideration Shares”). The Consideration Shares are to be held escrow and released in accordance with performance targets over an evaluation period of 3 years from January, 2026 to December, 2028.
Performance Targets
January 1, 2026 – December 31,
2026:
The target company shall achieve audited revenue of no less than RMB 750 million.
January 1, 2027 – December 31,
2027:
The target company shall achieve audited revenue of no less than RMB 1.3 billion.
January 1, 2028 – December 31,
2028:
The target company shall achieve audited revenue of no less than RMB 2.3 billion.
The consideration shares shall be subject to adjustment in accordance with the agreed terms. If the seller fails to meet the agreed performance targets in any assessment period, the number of shares to be released for that period (representing one-fifth of the total consideration shares) shall be deducted based on the agreed formula. The deducted consideration shares will be cancelled by the company. Conversely, if the seller exceeds the performance target by more than 50% in any assessment period, the excess revenue may be used to offset shortfalls from any previous assessment periods.
Future Biotechnology Group is an innovative technology enterprise focused on the biopharmaceutical sector. Its core businesses include biopharmaceutical research and development, genetic testing, medical devices, and pharmaceutical sales. The company is also comprehensively advancing its “AI Intelligent Manufacturing” strategy, deeply integrating artificial intelligence into key areas such as drug discovery, manufacturing processes, and precision medicine, continuously enhancing R&D efficiency and industrial commercialization capabilities. In addition, the group has established long-term and stable strategic partnerships with multiple medical institutions.
Ping An Biomedical Co., Ltd stated that this strategic investment aligns with the company’s long-term development strategy of “technology empowering healthcare.” Through synergistic cooperation with Future Biotechnology Group, the company will further integrate biopharmaceutical R&D, clinical translation, and industrial resources, accelerate the large-scale application of innovative technologies, and enhance overall industry competitiveness.
Against the backdrop of the biopharmaceutical industry’s transition toward high-quality development, industrial integration with clear technological pathways, well-defined performance targets, and robust incentive mechanisms is expected to unlock long-term growth potential. Through this strategic investment, Ping An Bio has laid a solid foundation for its continued expansion in the biopharmaceutical sector.
About Ping An Biomedical Co., Ltd
Ping An Biomedical Co., Ltd. is a one-stop SCM service provider in the apparel industry. It is also a forward-thinking company dedicated to delivering innovative solutions in healthcare and biomedical technology.
Safe Harbor and Informational Statement
This announcement contains “forward-looking” statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, including, without limitation, those with respect to the objectives, plans and strategies of the Company set forth herein and those preceded by or that include the words “believe,” “expect,” “anticipate,” “future,” “will,” “intend,” “plan,” “estimate” or similar expressions, are “forward-looking statements”. Although the Company’s management believes that such forward-looking statements are reasonable, it cannot guarantee that such expectations are, or will be, correct. These forward looking statements involve a number of risks and uncertainties, which could cause the Company’s future results to differ materially from those anticipated. These forward-looking statements can change as a result of many possible events or factors not all of which are known to the Company, which may include, without limitation, our ability to timely and accurately respond to changes in fashion trends and consumer preferences; management of customer concentration risk; reliance on third parties for supplies of raw materials, manufacturing services and transport infrastructure; changes in government policy in China; China’s overall economic conditions and local market economic conditions; our ability to expand through strategic acquisitions and establishment of new locations; compliance with government regulations; legislation or regulatory environments; geopolitical events, and other events and/or risks outlined in Ping An Biomedical Co., Ltd’s filings with the U.S. Securities and Exchange Commission. All information provided in this press release is as of the date of the issuance, and Ping An Biomedical Co., Ltd does not undertake any obligation to update any forward-looking statement, except as required under applicable law.
For more information, please contact:
Ping An Biomedical Co., Ltd.
Email: corpsec@pingan365.vip
Celestia Investor Relations
Email: investors@celestiair.com